Virios Therapeutics (VIRI) Competitors

$1.79 -0.02 (-1.10%)

As of 05/22/2026

VIRI vs. PYXS, GNLX, ACOG, OKUR, and THAR

Should you buy Virios Therapeutics stock or one of its competitors? MarketBeat compares Virios Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virios Therapeutics include Pyxis Oncology (PYXS), Genelux (GNLX), Alpha Cognition (ACOG), OnKure Therapeutics (OKUR), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry.

How does Virios Therapeutics compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Pyxis Oncology currently has a consensus target price of $6.83, suggesting a potential upside of 248.64%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Pyxis Oncology is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Pyxis Oncology has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Virios Therapeutics' return on equity of -130.33% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Virios Therapeutics	N/A	-130.33%	-115.00%

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 10.6% of Pyxis Oncology shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Pyxis Oncology had 12 more articles in the media than Virios Therapeutics. MarketBeat recorded 12 mentions for Pyxis Oncology and 0 mentions for Virios Therapeutics. Pyxis Oncology's average media sentiment score of 0.48 beat Virios Therapeutics' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Neutral
Virios Therapeutics	Neutral

Virios Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. Virios Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	8.96	-$79.62M	-$1.31	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Pyxis Oncology beats Virios Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Genelux has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

In the previous week, Genelux had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Genelux and 0 mentions for Virios Therapeutics. Genelux's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company	Overall Sentiment
Genelux	Neutral
Virios Therapeutics	Neutral

Genelux currently has a consensus price target of $18.00, suggesting a potential upside of 516.44%. Given Genelux's stronger consensus rating and higher possible upside, equities research analysts clearly believe Genelux is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

37.3% of Genelux shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Virios Therapeutics' return on equity of -130.33% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Virios Therapeutics	N/A	-130.33%	-115.00%

Virios Therapeutics has lower revenue, but higher earnings than Genelux. Virios Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Summary

Genelux beats Virios Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Virios Therapeutics has lower revenue, but higher earnings than Alpha Cognition. Virios Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.46	-$20.67M	-$1.35	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Alpha Cognition has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Alpha Cognition currently has a consensus target price of $16.00, suggesting a potential upside of 173.50%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Virios Therapeutics	N/A	-130.33%	-115.00%

In the previous week, Alpha Cognition had 6 more articles in the media than Virios Therapeutics. MarketBeat recorded 6 mentions for Alpha Cognition and 0 mentions for Virios Therapeutics. Alpha Cognition's average media sentiment score of 0.56 beat Virios Therapeutics' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Overall Sentiment
Alpha Cognition	Positive
Virios Therapeutics	Neutral

9.1% of Virios Therapeutics shares are owned by institutional investors. 14.0% of Alpha Cognition shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Alpha Cognition beats Virios Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to OnKure Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Virios Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

OnKure Therapeutics' return on equity of -61.02% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
OnKure Therapeutics	N/A	-61.02%	-55.99%

In the previous week, OnKure Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for OnKure Therapeutics and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 equaled OnKure Therapeutics'average media sentiment score.

Company	Overall Sentiment
Virios Therapeutics	Neutral
OnKure Therapeutics	Neutral

OnKure Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 541.33%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

OnKure Therapeutics beats Virios Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Virios Therapeutics compare to Tharimmune?

Virios Therapeutics (NASDAQ:VIRI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Virios Therapeutics' return on equity of -130.33% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Tharimmune	N/A	-588.45%	-264.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Tharimmune	Neutral

Summary

Virios Therapeutics beats Tharimmune on 7 of the 9 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIRI vs. The Competition

Export

Metric	Virios Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.47M	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	-6.63	1.46	20.99	25.66
Price / Sales	N/A	119.63	560.30	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	8.95	7.59	10.41	7.14
Net Income	-$5.30M	-$3.64M	$3.57B	$335.98M
7 Day Performance	5.29%	3.01%	6.41%	4.15%
1 Month Performance	29.71%	76.62%	3.55%	2.54%
1 Year Performance	-65.84%	126.61%	34.12%	35.06%

Virios Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIRI Virios Therapeutics	N/A	$1.79 -1.1%	N/A	-65.8%	$34.47M	N/A	N/A	5
PYXS Pyxis Oncology	3.5827 of 5 stars	$1.91 -5.4%	$6.83 +257.8%	+59.3%	$127.98M	$13.86M	N/A	60
GNLX Genelux	1.6694 of 5 stars	$2.80 -1.8%	$18.00 +542.9%	+13.2%	$127.79M	$10K	N/A	10	News Coverage
ACOG Alpha Cognition	4.2541 of 5 stars	$5.80 +0.9%	$16.00 +175.9%	-36.0%	$125.20M	$10.22M	N/A	N/A	Gap Down
OKUR OnKure Therapeutics	2.5936 of 5 stars	$3.30 +7.1%	$27.00 +718.2%	+95.8%	$124.42M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Competitors

VIRI vs. PYXS, GNLX, ACOG, OKUR, and THAR

How does Virios Therapeutics compare to Pyxis Oncology?

Summary

How does Virios Therapeutics compare to Genelux?

Summary

How does Virios Therapeutics compare to Alpha Cognition?

Summary

How does Virios Therapeutics compare to OnKure Therapeutics?

Summary

How does Virios Therapeutics compare to Tharimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Competitors

VIRI vs. PYXS, GNLX, ACOG, OKUR, and THAR

How does Virios Therapeutics compare to Pyxis Oncology?

Do analysts recommend PYXS or VIRI?

Which has more risk & volatility, PYXS or VIRI?

Is PYXS or VIRI more profitable?

Do insiders & institutionals hold more shares of PYXS or VIRI?

Does the media refer more to PYXS or VIRI?

Which has better valuation and earnings, PYXS or VIRI?

Summary

How does Virios Therapeutics compare to Genelux?

Which has more risk and volatility, GNLX or VIRI?

Does the media prefer GNLX or VIRI?

Do analysts recommend GNLX or VIRI?

Do insiders and institutionals have more ownership in GNLX or VIRI?

Is GNLX or VIRI more profitable?

Which has better earnings & valuation, GNLX or VIRI?

Summary

How does Virios Therapeutics compare to Alpha Cognition?

Which has preferable valuation and earnings, ACOG or VIRI?

Which has more volatility & risk, ACOG or VIRI?

Do analysts rate ACOG or VIRI?

Is ACOG or VIRI more profitable?

Does the media favor ACOG or VIRI?

Do insiders & institutionals hold more shares of ACOG or VIRI?

Summary

How does Virios Therapeutics compare to OnKure Therapeutics?

Do institutionals and insiders hold more shares of VIRI or OKUR?

Which has more risk & volatility, VIRI or OKUR?

Which has better valuation and earnings, VIRI or OKUR?

Is VIRI or OKUR more profitable?

Does the media refer more to VIRI or OKUR?

Do analysts recommend VIRI or OKUR?

Summary

How does Virios Therapeutics compare to Tharimmune?

Which has more risk and volatility, VIRI or THAR?

Which has higher earnings and valuation, VIRI or THAR?

Do institutionals & insiders believe in VIRI or THAR?

Is VIRI or THAR more profitable?

Do analysts recommend VIRI or THAR?

Does the media prefer VIRI or THAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools